Vitamin d and levomefolate

FDA label, PureTek Corporation, oral, effective 2023-12-05. Full label on DailyMed

Patient handout

Looking up MedlinePlus…

From MedlinePlus, U.S. National Library of Medicine

Quoted from the FDA label. Product labels differ by manufacturer and change over time; confirm against the label for the product you are using.

Dosing in kidney impairment

CONTRAINDICATIONS This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folixate ™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of Vitamin D, and hypervitaminosis D. WARNINGS AND PRECAUTIONS Tell your doctor if you have: kidney problems, thyroid disease.

Contraindications

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folixate ™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of Vitamin D, and hypervitaminosis D.

Safety data

Reported adverse events (FAERS)

Source: FDA Adverse Event Reporting System via openFDA

Liver injury (LiverTox)

LiverTox has no chapter for vitamin d and levomefolate. Check the label's hepatic warnings.

Source: LiverTox, NIDDK

Supply and cost

Price ladder

Not the price at the counter

These are not what a patient pays at the pharmacy counter. They are what pharmacies, health plans, and government buyers pay, before manufacturer rebates. A patient's cost depends on their insurance (copay, coinsurance, or deductible) or the pharmacy's cash price.

VA Federal Supply ScheduleCMS NADACMedicare Part D plan filesMedicaid State Drug Utilization Data

Products and NDCs

Recruiting clinical trials

Source: ClinicalTrials.gov API (NLM)Search on ClinicalTrials.gov